Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Neurocrine Biosciences (NBIX) Tops Q1 EPS by 77c, Beats on Revenue
May 5, 2026 4:14 PM EDTNeurocrine Biosciences (NASDAQ: NBIX) reported Q1 EPS of $1.94, $0.77 better than the analyst estimate of $1.17. Revenue for the quarter came in at $811 million versus the consensus estimate of $766.85 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
... More